Fig. 5From: c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancerSurvival analysis based on CTC and plasma cfDNA concentration in HR+/HER2− mBC. Kaplan–Meier analysis grouped by c-MET+ CTC (A, B) or EpCAM+ CTC (C, D) and cfDNA concentration. Patients with HR+/HER2− mBC were grouped into four (A, C) or two categories (B, D)Back to article page